Which stock wins in a head-to-head matchup between a leading Canadian cannabis producer and the top premium beer maker?
A drug once thought as dead could be rising from the ashes. Does Biogen's shocking news make the stock a buy now?
Great revenue and earnings growth made investors happy with the health insurer's latest performance.
The diagnostics information services company beat expectations on both the top and bottom lines.
Investors weren't exactly sure how to react to the clinical failure of a drug that works similarly to Gossamer's lead candidate.
These three cannabis stocks probably won't flounder for very much longer.
These stocks each have three secret ingredients for long-term investing success.
These solid companies have boosted their dividends by at least 67% over the last three years.
Don't be surprised if the beaten-down Canadian marijuana stock makes a comeback soon.
Which stock wins between these two biotechs?
A recall of its baby powder sparked worries about the healthcare giant's asbestos-related legal battles.
Plans to launch cannabis-infused beverages lit a fire beneath the beaten-down marijuana stock.
A potentially large new cannabis market is at hand in Canada. Here's what to look for.
Investors are excited about the potential for a settlement in opioid litigation.
Here's a quick rundown on how the healthcare giant performed.
Which stock wins in a one-on-one matchup between a leading Canadian cannabis producer and a top e-commerce company serving the cannabis industry?
It's growing. It's profitable. It's beating expectations. The other big Canadian pot stocks aren't.
Impressive quarterly results are lighting a fire beneath this Canadian marijuana stock.
All three of these top Canadian marijuana stocks are struggling. But a Jefferies analyst thinks that two out of three of them aren't bad.
MedMen says its approach is to go deep rather than wide now that the PharmaCann buyout has been scrapped.